A global provider of drug development and commercialization solutions and services has signed a new agreement extending its relationship with OmniComm Systems, Inc. for another seven years.    Under the terms of the agreement, the CRO will use OmniComm’s TrialOne eClinical solution to automate early phase studies at one of its U.S.-based clinical research units. The global CRO selected TrialOne, apart from its status as the market-leading eSource and site automation system for Pha...